

SHARE PURCHASE PLAN RAISES \$0.4 MILLION

Total Capital Raised including Placement is \$8.4 million

Adelaide, Australia, 12 August 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the completion of the Company's Share Purchase Plan (**SPP**).

The SPP was announced to the market on 17 July 2020 and closed at 5.00pm ACST on 7 August 2020. Valid applications for 2,296,250 new fully paid ordinary shares (**SPP Shares**) were received from 56 applicants, raising \$367,400.

The SPP applicants will be issued their SPP Shares at \$0.16 per share, being the same price as the \$8m placement completed on 15 July 2020 (**Placement**). The SPP shares are expected to be allotted on Monday 17 August 2020. A further announcement will be made on the date of allotment.

The amount raised under the SPP, together with the funds raised through the Placement, will be used to expand the Company's commercialisation activities for the APAS[®] Independence in Europe and the United States, continued APAS[®] technology development for the creation of new analysis modules, working capital and costs associated with the Placement and SPP.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak[®], was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS[®]) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beetling's- und Verwaltungs-GmbH. The APAS[®] instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

Contacts

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com